Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIOH-1: pritelivir versus foscarnet for acyclovir-resistant mucocutaneous HSV in immunocompromised patients
MOH_2022-06-12_011847Phase 3Completed
- Sponsor
- AiCuris
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pritelivir and foscarnet sodium in herpes simplex (HSV) (4 arms), sponsored by AiCuris. Started Feb 2022; status: completed.
02
Drugs
pritelivirfoscarnet sodium
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on MOH_2022-06-12_011847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-12_011847.